Jefferies Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jefferies Group’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,400	Closed	-$2.09M	–	1936
2022 Q1	$2.09M	Buy	+25,400	New	+$2.6M	0.01%	672
2021 Q4	–	Sell	-25,200	Closed	-$4.46M	–	2089
2021 Q3	$4.46M	Buy	+25,200	New	+$4.05M	0.03%	474
2021 Q2	–	Sell	-46,800	Closed	-$8.02M	–	2084
2021 Q1	$8.02M	Sell	46,800 -6,800	-13%	-$1.35M	0.07%	243
2020 Q4	$11.8M	Buy	53,600 +8,300	+18%	+$1.79M	0.09%	184
2020 Q3	$7.52M	Buy	45,300 +42,800	+1,712%	+$5.86M	0.08%	200
2020 Q2	$285	Hold	2,500	–	–	﹤0.01%	1020
2020 Q1	$192K	Sell	2,500 -33,000	-93%	-$2.96M	﹤0.01%	1688
2019 Q4	$4.58M	Buy	35,500 +26,600	+299%	+$2.57M	0.04%	558
2019 Q3	$693K	Sell	8,900 -84,500	-90%	-$7.93M	0.01%	1707
2019 Q2	$9.62M	Buy	93,400 +88,900	+1,976%	+$6.92M	0.07%	239
2019 Q1	$330K	Buy	+4,500	New	+$306K	﹤0.01%	1762
2018 Q4	–	Sell	-62,500	Closed	-$2.94M	–	2684
2018 Q3	$2.94M	Buy	+62,500	New	+$3.48M	0.02%	797

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group's MRTX Position: Q3 2022 in Review

Jefferies Group increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 114% in Q3 2022, buying an estimated $831K and bringing the position to 21,049 shares worth $1.47M. The position accounts for 0.01% of the portfolio, ranked #698.

Jefferies Group first reported a position in MRTX in Q3 2018 and has held it in 14 quarters since. The position peaked at $21.4M in Q4 2020. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

Jefferies Group held 21,049 shares of Mirati Therapeutics, Inc. Common Stock worth $1.47M as of Q3 2022.
Jefferies Group bought 11,233 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $831K.
Mirati Therapeutics, Inc. Common Stock made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #698 holding.
Jefferies Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and has held it in 14 quarters since.
Jefferies Group's Mirati Therapeutics, Inc. Common Stock position peaked at $21.4M in Q4 2020.
243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.